Company Dossier · Health Care
Universal Health Services
- S&P 500
- Russell 1000
What Universal Health Services is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $18.1 billion, up 10% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.85 billion, down 5.6% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.95 billion, down 5.0% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.97 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 28, 2026): sentiment 0.20 on a −1 to +1 scale (mixed), confidence 0.60 of 1.Palanor Discourse
- Guidance in the last 90 days: 0 outlook figures raised, 2 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 25, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q1 2026: $0.1 million on the open market.SEC Form 4
- 597 institutional managers reported a position at June 30, 2026 (−59 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 6 (4 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Universal Health Services is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Retrenching · Hedging
Expanding ↔ Retrenching
Retrenching
- Capital spending22nd pct
- Debt raised—
- Buybacks vs capex41st pct
- Hiring filings4th pct
- Deals and private raises49th pct
- Patent publications65th pct
Confident ↔ Hedging
Hedging
- Call sentiment33rd pct
- Call confidence35th pct
- Guidance changes3rd pct
- Risk factors added81st pct
- Insider open-market trades—
- − Guidance changes
- + Risk factors added
- − Call sentiment
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver80th pct
- Stress filings48th pct
Credit
How these are built →Universal Health Services's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$4.9B
- Due within a year $0.8B
- Longer term $4.1B
- Default point $2.8B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
$0.6B
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Aug 11, 2026 | $600M | 5.500% | 2031 (5y) | +113bp | 5.514% |
| Sep 17, 2024 | $500M | 4.625% | 2029 (5y) | +120bp | 4.634% |
From the pricing term sheets Universal Health Services filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 13, 2026Patent
- Aug 21, 20268-KMaterial agreement signedItem 1.01
- Aug 13, 20268-KMaterial agreement signedItem 1.01
- Jul 21, 20268-KMaterial agreement signedItem 1.01
- Jul 7, 2026LobbyingLobbying report (MR. KYLE MULROY)third_quarter 2026
- May 27, 2026LobbyingLobbying report (WASHINGTON STRATEGIC CONSULTING)first_quarter 2026 · $0.0 million
- May 22, 20268-KShareholder vote resultsItem 5.07
- May 21, 20268-KDirector or officer changeItem 5.02
- Apr 24, 20268-KMaterial agreement signedItem 1.01
- Apr 21, 2026LobbyingLobbying report (WASHINGTON STRATEGIC CONSULTING)first_quarter 2026 · $0.0 million
- Apr 7, 2026Patent
- Mar 30, 20268-KDirector or officer changeItem 5.02
- Feb 25, 202610-KAnnual report (10-K)0 risk factors added, 0 removed
- Jan 21, 2026LobbyingLobbying report (WASHINGTON STRATEGIC CONSULTING)fourth_quarter 2025 · $0.0 million
- Dec 31, 20258-KDirector or officer changeItem 5.02
- Oct 20, 2025LobbyingLobbying report (WASHINGTON STRATEGIC CONSULTING)third_quarter 2025 · $0.0 million
- Jul 22, 2025Patent
- Jul 13, 2025LobbyingLobbying report (WASHINGTON STRATEGIC CONSULTING)second_quarter 2025 · $0.0 million
- May 15, 20258-KShareholder vote resultsItem 5.07
- Apr 17, 2025LobbyingLobbying report (WASHINGTON STRATEGIC CONSULTING)first_quarter 2025 · $0.0 million
- Mar 20, 20258-KDirector or officer changeItem 5.02
- Feb 26, 202510-KAnnual report (10-K)1 risk factors added, 3 removed
- Jan 20, 2025LobbyingLobbying report (WASHINGTON STRATEGIC CONSULTING)fourth_quarter 2024 · $0.0 million
- Nov 12, 2024Patent
- Feb 27, 202410-KAnnual report (10-K)2 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Tenet Healthcare THC | $21.8B | $3.0B | Jun 30, 2026 |
| Encompass Health EHC | $6.2B | $0.4B | Jun 30, 2026 |
| HCA Healthcare HCA | $76.4B | $7.9B | Mar 31, 2026 |
| IQVIA IQV | $16.6B | $2.1B | Mar 31, 2026 |
| GE HealthCare GEHC | $21.0B | — | Mar 31, 2026 |
| Boston Scientific BSX | $21.0B | $3.6B | Jun 30, 2026 |
| Regeneron Pharmaceuticals REGN | $15.5B | $3.8B | Jun 30, 2026 |
| Viatris VTRS | $14.7B | $1.9B | Jun 30, 2026 |